New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
Preoperative Chemoradiotherapy for Resectable Gastric Cancer
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
NEJM at ESMO — Pembrolizumab in HER2+ Gastric Cancer
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
NEJM at ESMO — Preoperative Chemoradiotherapy for Resectable Gastric Cancer
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
NEJM at ESMO — Preoperative Chemoradiotherapy for Resectable Gastric Cancer
In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of Medical Oncology annual meeting. . . .
The New England Journal of Medicine: Search Results in Hematology/Oncology
Pembrolizumab in HER2-Positive Gastric Cancer
The addition of pembrolizumab to trastuzumab and chemotherapy in patients with gastric cancer improved both progression-free and overall survival as compared with trastuzumab and chemotherapy alone.
The New England Journal of Medicine: Search Results in Hematology/Oncology
NEJM at ESMO — Pembrolizumab in HER2+ Gastric Cancer
In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of Medical Oncology annual meeting. . . .
The New England Journal of Medicine: Search Results in Hematology/Oncology
Preoperative Chemoradiotherapy for Resectable Gastric Cancer
In a trial comparing chemotherapy and preoperative chemoradiotherapy with perioperative chemotherapy in patients with resectable gastric or GE junction cancer, no significant difference in overall survival was noted.
The New England Journal of Medicine: Search Results in Hematology/Oncology
NEJM at ESMO — Pembrolizumab in HER2+ Gastric Cancer
In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of Medical Oncology annual meeting. . . .
The New England Journal of Medicine: Search Results in Gastroenterology
Pembrolizumab in HER2-Positive Gastric Cancer
The addition of pembrolizumab to trastuzumab and chemotherapy in patients with gastric cancer improved both progression-free and overall survival as compared with trastuzumab and chemotherapy alone.
The New England Journal of Medicine: Search Results in Gastroenterology